CN114984159B - 一种慢痞消颗粒及其制备方法 - Google Patents
一种慢痞消颗粒及其制备方法 Download PDFInfo
- Publication number
- CN114984159B CN114984159B CN202210581306.5A CN202210581306A CN114984159B CN 114984159 B CN114984159 B CN 114984159B CN 202210581306 A CN202210581306 A CN 202210581306A CN 114984159 B CN114984159 B CN 114984159B
- Authority
- CN
- China
- Prior art keywords
- parts
- solution
- mobile phase
- drying
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000008187 granular material Substances 0.000 title claims abstract description 27
- 206010000060 Abdominal distension Diseases 0.000 title claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 238000001035 drying Methods 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 26
- 238000007873 sieving Methods 0.000 claims abstract description 17
- 239000007779 soft material Substances 0.000 claims abstract description 16
- 238000007670 refining Methods 0.000 claims abstract description 15
- 239000000080 wetting agent Substances 0.000 claims abstract description 15
- 239000003085 diluting agent Substances 0.000 claims abstract description 14
- 241000218176 Corydalis Species 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 239000000052 vinegar Substances 0.000 claims abstract description 8
- 235000021419 vinegar Nutrition 0.000 claims abstract description 8
- 238000000227 grinding Methods 0.000 claims abstract description 5
- 238000010992 reflux Methods 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims abstract description 3
- 238000000605 extraction Methods 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 32
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 29
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 29
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 26
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 26
- 229940052490 naringin Drugs 0.000 claims description 26
- 229930019673 naringin Natural products 0.000 claims description 26
- 238000012546 transfer Methods 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 11
- 235000019425 dextrin Nutrition 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 7
- 240000004307 Citrus medica Species 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 240000001659 Oldenlandia diffusa Species 0.000 claims description 6
- 235000004347 Perilla Nutrition 0.000 claims description 6
- 244000124853 Perilla frutescens Species 0.000 claims description 6
- 240000007164 Salvia officinalis Species 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 235000005412 red sage Nutrition 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 5
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 5
- 241000220317 Rosa Species 0.000 claims description 5
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 5
- 241000756042 Polygonatum Species 0.000 claims description 4
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 241001127714 Amomum Species 0.000 claims description 3
- 241000092665 Atractylodes macrocephala Species 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000008569 process Effects 0.000 description 21
- 239000003814 drug Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000011835 investigation Methods 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 8
- 208000007882 Gastritis Diseases 0.000 description 7
- 208000023652 chronic gastritis Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241000132012 Atractylodes Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种慢痞消颗粒及其制备方法。本发明慢痞消颗粒制备方法包括如下步骤:1)将丹参、香橼、太子参、醋延胡索、玉竹、生白术、玫瑰花、乌梅、紫苏梗、白花蛇舌草、砂仁和炙甘草的饮片按比例混合,加水回流进行提取,过滤并收集滤液,得到提取液;2)对步骤1)提取液精制,得到精制液;3)将步骤2)精制液浓缩至稠膏,得到浓缩液;4)将步骤3)浓缩液干燥,得到干浸膏;5)将步骤4)干浸膏研磨过筛后与稀释剂混合,加入润湿剂制作软材,将软材过筛制粒后干燥、整粒,即得慢痞消颗粒。本发明通过考察各工艺参数,确定了最优工艺和最优参数,能最大程度的保留有效成分含量,颗粒携带、服用方便,克服了传统汤剂及配方颗粒的不足。
Description
技术领域
本发明涉及中药制剂技术领域,尤其涉及一种慢痞消颗粒及其制备方法。
背景技术
根据经典的Correa模式,肠型胃癌发生的主要途径即由正常胃黏膜→非萎缩性胃炎→萎缩性胃炎→肠上皮化生→异型增生→胃腺癌。采取有效的手段阻断或逆转慢性胃炎向胃癌的恶性转化,对胃癌的预防具有重要的临床与社会意义。
“慢痞消”源于国医大师路志正教授临床治疗慢性胃炎的经验代表方,由太子参、丹参、玉竹、香橼等12味中药配伍而成,具有调气养阴、活血解毒的功效。数十年的临床应用及观察证明,慢痞消治疗慢性胃炎、胃癌癌前病变患者疗效显著。本课题组前期以国医大师路志正教授临床经验为指导,开发出一种用于阻断慢性胃炎“炎癌转化”的中药组合物(CN113925937 A),利用MNNG多因素综合造模法建立慢性胃炎“炎癌转化”大鼠模型,初步证实了该中药组合物能改善大鼠胃粘膜病理状态,缓解胃粘膜炎症反应,恢复胃酸分泌功能,调节胃内菌群微环境,从根本上逆转慢性胃炎“炎癌转化”进程。
在临床上,该中药组合物以汤剂或配方颗粒的形式应用。与传统汤剂相比,配方颗粒具有携带方便、服用方便等优势,但是仍然存在服用调配的不便利性,并且流通范围有限,不能够适应现代用药的需求。因此,在中医药理论的指导下,结合现代制药技术进一步进行慢痞消制剂开发,对于改变慢性胃炎“炎癌转化”临床药物缺乏的现状具有重要意义。
发明内容
本发明的目的是提供一种慢痞消颗粒及其制备方法,通过优化确定了最佳的颗粒剂的制备工艺。
本发明提供的一种慢痞消颗粒的制备方法,包括如下步骤:
1)将丹参、香橼、太子参、醋延胡索、玉竹、生白术、玫瑰花、乌梅、紫苏梗、白花蛇舌草、砂仁和炙甘草的饮片按比例混合,加水回流进行提取,过滤并收集滤液,得到提取液;
2)对步骤1)所述提取液进行精制以除去杂质,得到精制液;
3)将步骤2)所述精制液浓缩至稠膏,得到浓缩液;
4)将步骤3)所述浓缩液干燥,得到干浸膏;
5)将步骤4)所述干浸膏研磨过筛后与稀释剂混合,加入润湿剂制作软材,将所述软材过筛制粒后干燥、整粒,即得所述慢痞消颗粒。
上述的制备方法,步骤1)中,各饮片的质量份数如下:丹参10~20份、香橼 3~10份、太子参9~30份、醋延胡索3~24份、玉竹6~24份,生白术6~30份、玫瑰花3~18份、乌梅3~12份、紫苏梗5~24份、白花蛇舌草15~60份、砂仁3~6份、炙甘草2~12份;
优选地,丹参10~15份、香橼3~10份、太子参9~30份、醋延胡索3~12份、玉竹6~12份,生白术6~15份、玫瑰花3~9份、乌梅3~6份、紫苏梗5~12份、白花蛇舌草15~30份、砂仁3~4份、炙甘草2~6份。
进一步优选地,各饮片的质量份数如下:丹参15份、香橼9份、太子参15份、醋延胡索12份、玉竹12份,生白术15份、玫瑰花9份、乌梅6份、紫苏梗12份、白花蛇舌草30份、砂仁4份、炙甘草6份。
上述的制备方法,步骤1)中,所述提取的条件可如下:以重量计,第一次加 10倍量水提取1~1.5h,第二次在滤渣中加入8倍量水提取1~1.5h,第三次在滤渣中加入8倍量水提取1~1.5h,共提取3次;优选地,所述提取的条件如下:以重量计,第一次加10倍量水提取1h,第二次在滤渣中加入8倍量水提取1h,第三次在滤渣中加入8倍量水提取1h,共提取3次。
上述的制备方法,步骤2)中,所述精制可包括如下步骤:将所述提取液离心,收集上清液;所述离心的转速可为2000~5000r/min(如3000r/min),时间可为15~40 min(如30min)。
上述的制备方法,步骤3)中,所述稠膏的密度可为1.05g/mL~1.10g/mL,60℃测;
分三次提取,所述浓缩可包括如下步骤:将第一次提取液的精制液浓缩至稠膏,再加入第二次提取液的精制液浓缩至稠膏,再加入第三次提取液的精制液浓缩至稠膏;优选地,每次提取液的精制液可为所述提取液的离心上清液。
上述的制备方法,步骤4)中,所述干燥可为真空干燥;
所述干燥的温度可为60℃~70℃,具体可为60℃或70℃;所述干燥的时间可根据温度进行调节,具体为在所述温度下干燥至干浸膏的含水率小于5%。
上述的制备方法,步骤5)中,所述干浸膏与所述稀释剂的质量比可为 (0.75~1.25):1,具体可为0.75:1、1:1或1.25:1;
所述稀释剂可为糊精或可溶性淀粉;
所述润湿剂可为质量分数为85%~95%的乙醇的水溶液。
优选地,所述稀释剂为糊精,所述润湿剂为质量分数为95%的乙醇的水溶液;
优选地,所述稀释剂为可溶性淀粉,所述润湿剂为质量分数为90%的乙醇的水溶液。
上述的制备方法,步骤5)中,所述干浸膏研磨过筛为过4号筛;
所述软材过筛制粒为过1号筛制粒;
所述干燥的温度可为60~70℃(如60℃),时间可为30~90min(如1h)。
本发明中,通过比较柚皮苷、丹酚酸B的转移率和/或比较出膏率优化制备方法;
柚皮苷和丹酚酸B含量的测定采用高效液相色谱法,色谱条件如下:
色谱柱:C18柱,250mm×4.6mm,5μm;
流动相:流动相A为乙酸,流动相B为乙腈,流动相C为水;
洗脱方式:梯度洗脱,洗脱程序如下:0~15min,流动相A的体积分数为3.8%,流动相B的体积分数为15%;15~15.01min,流动相A的体积分数为3.8%,流动相B 的体积分数由15%上升至16%;15.01~30min,流动相A的体积分数3.8%,流动相B 的体积分数为16%;
流速:1.2mL/min;
柱温:35℃;
检测波长:286nm;
进样量:10μL。
本发明进一步提供了由上述任一项所述的制备方法制备得到的慢痞消颗粒。
本发明具有如下有益效果:
(1)本发明通过对提取、精制、浓缩、干燥、成型工艺参数的考察,确定了最优工艺和最优参数,能最大程度的保留有效成分的含量。
(2)本发明制备的颗粒携带、服用方便,克服了传统汤剂及配方颗粒的不足。
附图说明
图1为实施例2中不同精制方法溶化性实验的对比照片。
具体实施方式
下面结合具体实施方式对本发明进行进一步的详细描述,给出的实施例仅为了阐明本发明,而不是为了限制本发明的范围。以下提供的实施例可作为本技术领域普通技术人员进行进一步改进的指南,并不以任何方式构成对本发明的限制。
下述实施例中所使用的实验方法如无特殊说明,均为常规方法;所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
下述实施例中各中药饮片的来源如下:丹参(批号2103059,产地山东,购自北京市双桥燕京中药饮片厂);香橼(批号2003033,产地四川,购自北京市双桥燕京中药饮片厂);太子参(批号20200926,产地浙江,购自北京本草方源有限公司);玉竹(批号20201020,产地浙江,购自北京本草方源有限公司);醋延胡索(批号 20201117,产地浙江,购自北京本草方源有限公司);生白术(批号20200526,产地安徽,购自北京本草方源有限公司);玫瑰花(批号20201117,产地甘肃,购自北京本草方源有限公司);乌梅(批号20200909,产地福建,购自北京本草方源有限公司);紫苏梗(批号202001004,产地河北,购自北京本草方源有限公司);白花蛇舌草(批号20201127,产地江西,购自北京本草方源有限公司);砂仁(批号20201126,产地广东,购自北京本草方源有限公司);炙甘草(批号20201110,产地甘肃,购自北京本草方源有限公司)。
糊精(萨恩科学技术有限公司);可溶性淀粉(上海阿拉丁生化科技股份有限公司);乳糖(上海麦克林生化科技有限公司)。
1号、4号、5号标准检验筛(北京祥宇伟业仪器设备有限公司)。
下述实施例中采用HPLC法测定柚皮苷和丹酚酸B含量。
实验仪器:Waters2998/e2695高效液相色谱仪(沃特世科技有限公司,DAD检测器,Empower 3色谱工作站);Agilent Zorbax SB-C18色谱柱(250mm×4.6mm,5μm)。
实验材料:柚皮苷对照品(购自中国食品药品检定研究院,含量以91.7%计,批号110722-201815);丹酚酸B(购自中国食品药品检定研究院,含量以96.6%计,批号111562-201917)。
色谱条件:Agilent C18(250mm×4.6mm,5μm);以乙酸(A)-乙腈(B)-水 (C)为流动相,按照表1条件梯度洗脱;流速为1.2ml/min,柱温为35℃;检测波长: 286nm;理论塔板数按丹酚酸B计算应不低于10000。
表1、梯度洗脱程序表
对照品溶液的制备:精密称取柚皮苷和丹酚酸B对照品适量,加入甲醇溶液,制成含柚皮苷浓度为85.0128μg/mL,丹酚酸B浓度为149.0944μg/mL的混合对照品溶液。
供试品溶液的制备:根据处方各药材比例,称取饮片,按照正交试验表进行提取,用200目筛过滤提取液,合并相应的提取液,调整体积至2L,摇匀。取提取液1ml,加入等量甲醇,摇匀,10000r/min离心10min,取上清液,即得。
转移率的计算公式如下:转移率=提取液中指标性成分的总量/药材中指标性成分的总量*100%。
实施例1、提取工艺的考察
处方:丹参15g、香橼9g、太子参15g、玉竹12g、醋延胡索12g、生白术15 g、玫瑰花9g、乌梅6g、紫苏梗12g、白花蛇舌草30g、砂仁4g、炙甘草6g。
1、吸水量考察
由于煎煮时,第一次加入水时饮片会吸水,故考察饮片的吸水量。称取一个处方量的慢痞消饮片,加入10倍量水,浸泡12小时,滤过,量取滤液体积。发现吸水量约为慢痞消饮片总重量的2.0倍。
2、正交试验设计
全方用水提取,以提取物中柚皮苷和丹酚酸B含量数据归一化后所得综合评分为考察指标,选择加水倍量、提取时间、提取次数为影响因素,每个因素设计三个水平,采用L9(34)正交表,考察慢痞消的提取工艺,因素水平设计见表2。
表2正交试验因素水平表
根据上述吸水量考察结果,第二次和第三次提取时加水倍量均减少两个倍量,例如表2中加水倍量10(8,8)分别表示第一次加水倍量为10倍,第二次和第三次均为8 倍。
实验过程如下:取1个处方量的全方饮片,按照正交试验表加水回流提取(表3)。取提取液适量,供试品溶液,HPLC法测定柚皮苷和丹酚酸B的含量。取适量提取液浓缩,转移至已知重量的蒸发皿中,蒸干,60℃减压干燥至恒重,计算出膏率。每组平行操作两份。根据含量测定结果进行多指标综合评分,评分时以各指标的最大值为参照,将数据进行归一化,再给出各指标的权重。本研究中,柚皮苷和丹酚酸B均设为0.5。以综合值进行统计分析,其中综合评分W=(0.5X/Xmax+0.5Y/Ymax)×100(X 为柚皮苷含量;Xmax为最大柚皮苷含量;Y为丹酚酸B含量;Ymax为最大丹酚酸B含量; W为综合评分)。
表3正交试验表
表4指标性成分总含量方差分析
通过SPSS20软件进行数据处理,方差分析结果表明,各因素对试验结果的影响次序为提取次数(C)>加水倍量(A)>提取时间(B),其中提取时间(B)对试验结果没有显著影响,而提取次数(C)和加水倍量(A)对试验结果有显著的影响(表 4)。
多重比较结果显示,A因素的影响水平为A2>A1>A3,其中A2显著高于A3和A1,选择提取效率的最高的A2,即加入10倍量水提取。B因素的影响水平为B2>B3>B1,三者间均无显著性差异,选择提取时间最少的B1,即提取1h。C因素的影响水平为 C2>C3>C1,其中C3和C2显著高于C1,C3和C2之间无显著差异,选择提取效率较高的 C2,即提取2次。综上,优选工艺为A2B1C2(工艺4)。根据K值直观分析发现,A2B1C3最好(加10倍量水提取3次,每次1h),正交表中无此实验,应补做。因此需要对上述二种工艺(A2B1C2和A2B1C3)进行验证实验。
3、验证实验
按照1倍量处方量称取慢痞消药材,根据A2B1C2和A2B1C3的因素水平表进行验证实验。此外,由于A2B2C3综合评分最高,且C2和C3间无显著差异,因此,还对A2B2C2和A2B2C3进行了验证实验。
收集前两次水煎液合并,定容至2L容量瓶,第三次水煎液定容至1L容量瓶。制备供试品溶液,HPLC法测定丹酚酸B和柚皮苷的含量,计算二者的转移率,考察是否有必要提取三次。
结果显示,与工艺A2B1C2相比,工艺A2B1C3中柚皮苷的转移率增加了22.03%,丹酚酸B的转移率增加了12.45%。与工艺A2B2C2相比,工艺A2B2C3中柚皮苷的转移率增加了17.77%,丹酚酸B的转移率增加了13.12%。说明提取二次仍有较多的柚皮苷和丹酚酸B未被提取出来。
由SPSS统计软件比较工艺A2B1C3和A2B2C3,结果显示,两种工艺所得的柚皮苷转移率P=0.591(P>0.05),无显著性差异;丹酚酸B转移率P=0.143(P>0.05),无显著性差异。考虑到工业生产节约成本,选择提取时间短的工艺A2B1C3。
所以最终确定工艺为A2B1C3,即第一次加10倍量水提取1h,第二次和第三次分别加入8倍量水,提取1h,共提取3次。
结果显示工艺A2B1C3的出膏率约为38.29%,每个慢痞消的出膏量为55.52g,日服用量较大,拟通过精制工艺除杂,降低出膏率。
实施例2、精制工艺考察
采用实施例1确定的最优的提取工艺:按1倍处方量称取慢痞消药材,第一次加 10倍量水,回流提取1h,过滤。第二次和第三次分别在滤渣中加入8倍量水,回流提取1h,过滤。合并3次滤液,调整体积到3L,搅拌均匀,平均量取3份,每份 1L。每组平行操作三份。测定柚皮苷和丹酚酸B的含量,计算转移率。
分别按照如下方法对精制工艺进行考察,计算每种精制工艺的出膏率:
三份原液:浓缩后转移至已知重量的蒸发皿中,水浴浓缩至粘稠状态,60℃减压干燥,计算出膏率,干膏粉过四号筛备用。
三份离心液:3000r/min离心30min,取上清液,浓缩后转移至已知重量的蒸发皿中,水浴浓缩至粘稠状态,60℃减压干燥,计算出膏率,干膏粉过四号筛备用。
三份醇沉液:浓缩至约0.5g生药/mL,加入95%乙醇至含醇量60%,室温下醇沉12h抽滤,滤液浓缩后转移至已知重量的蒸发皿中,水浴浓缩至粘稠状态,60℃减压干燥,计算出膏率,干膏粉过四号筛备用。
结果显示:3种精制方法所得的柚皮苷转移率P=0.199(P>0.05),不具有显著性差异;丹酚酸B转移率P=0.042(P<0.05)。具有显著性差异,离心组>醇沉组。
参照2020版《中国药典》四部颗粒剂项下的溶化性实验检验项,考察原液组、离心组和醇沉组干膏粉的溶化性。结合溶化性考察,选择最优的精制工艺。结果显示,原液组冷却后底部有大量沉淀,醇沉组冷却后有沉淀析出,离心组冷却后无明显沉淀(图1)。
综上所述,离心组干膏粉溶化性最优,并且具有和汤剂最接近的物质基础,考虑工业生产的便捷性,选择离心除杂的精制方式。
实施例3、浓缩工艺考察
称取1倍处方量的慢痞消药材,按照优选后的提取方式提取,分别取三次滤液。3000r/min离心30min后,取上清液,每次上清液平均分为2份,一份为三次提取液单独浓缩组,一份为合并浓缩组。平行操作2份。
三次提取液单独浓缩组:将3次提取液分别浓缩至相对密度为1.05g/mL(60℃测密度),分别转移至已知恒重的蒸发皿中,60℃水浴浓缩至稠膏。
合并浓缩组:第一次提取液浓缩至一定程度后,再加入第二次提取液,一起浓缩至一定程度,再加入第三次提取液,一起浓缩至相对密度为1.05g/mL(60℃测密度),转移至已知恒重的蒸发皿中,60℃水浴浓缩至稠膏。
将三次提取液单独浓缩组和合并浓缩组稠膏于60℃减压干燥,计算出膏率,干膏研磨粉碎,过4号筛备用。取上述干膏粉1.0g,精密称定,置于250mL锥形瓶中,精密加入甲醇100mL,称重,超声10min,放冷,补足重量,摇匀。取上清液10000 r/min离心10min,取上清液,得供试品溶液。测定柚皮苷和丹酚酸B含量,计算转移率。
由SPSS统计软件分析得,两种浓缩方式所得的柚皮苷的转移率P=0.631(P>0.05),无显著性差异;丹酚酸B的转移率P=0.372(P>0.05),无显著性差异;出膏率P=0.125(P>0.05),无显著性差异。结合生产实际,精制后选择合并浓缩,生产时可采用第一次提取液先行浓缩至密度约为1.05g/mL(60℃),再加入第二次提取液浓缩至密度约为1.05g/mL(60℃),再加入第三次提取液浓缩至密度约为1.05 g/mL。
实施例4、干燥工艺考察
称取1倍处方量的慢痞消药材2份,按照实施例1优选后的提取方式提取,滤液用3000r/min离心30min后,取上清液,分别采用合并浓缩的方式浓缩至相对密度为1.05 g/mL(60℃测密度)。每份浓缩液平均分为2份,置于已知重量的蒸发皿中,第一份浓缩液分别于60℃和70℃干燥,第二份浓缩液分别于80℃和90℃干燥。从0h开始,每3 h取出称重,直至恒重,计算干燥失水率。平行操作2份。
干燥失水率=(测定时间点的膏重-干燥结束时的膏重)/干燥结束时的膏重×100%。
干膏研磨粉碎,过4号筛备用。取上述干膏粉1.0g,精密称定,置于250mL锥形瓶中,精密加入甲醇100mL,称重,超声10min,放冷,补足重量,摇匀。取上清液10000r/min离心10min,取上清液,得供试品溶液。测定柚皮苷和丹酚酸B含量,计算转移率。
实验结果显示,浸膏于60℃、70℃、80℃和90℃真空干燥箱干燥完成时间分别为87h、45h、39h和27h。测定干膏粉中柚皮苷和丹酚酸B的含量,经SPSS统计软件分析得知,不同干燥温度下柚皮苷转移率P=0.449(P>0.05),无显著性差异;丹酚酸B转移率P=0.007(P<0.05),有显著性差异,多重比较结果显示,60℃干燥时含量大于70℃、80℃和90℃。综上,选择对含量影响较小的60℃干燥。
实施例5、成型工艺考察
1稀释剂的筛选
分别以糊精、可溶性淀粉和乳糖为辅料,固定干浸膏(研磨,过4号筛)与辅料 1:1的比例混合均匀,用适量的90%乙醇为润湿剂制软材,过1号筛制粒,60℃干燥1h,整粒。以外观性状和溶化性为指标筛选稀释剂的种类。
(1)外观性状:对颗粒颜色和均匀度进行评价。
(2)溶化性检测方法:取单次服用剂量颗粒,加入200mL热水搅拌5min,颗粒全部溶化或呈混悬状态则说明颗粒溶化性合格。
结果可知,糊精和可溶性淀粉制得颗粒呈棕黄色,颜色均匀,溶化性好。乳糖制得颗粒颜色不均匀,溶化性差。且与乳糖相比,糊精和可溶性淀粉价格低廉,故选择糊精和可溶性淀粉为稀释剂。
2、润湿剂的筛选
将干浸膏(研磨,过4号筛)与辅料以1:1混合,分别加入85%、90%和95%的乙醇为润湿剂,制作软材。过1号筛制粒,60℃干燥1h,整粒。以软材性状、制粒难度和成型率为指标筛选润湿剂的种类。
颗粒成型率检测方法:将制备好的颗粒称定重量,先过1号筛,再过5号筛,收集能过1号筛但不能过5号筛的颗粒,称定重量。
成型率=过筛后颗粒的重量/过筛前颗粒重量×100%。
结果可知,以糊精为稀释剂时,选择95%乙醇作为润湿剂制成的软材松散无团块,能全部通过筛网,颗粒成型率为94.19%。以可溶性淀粉为稀释剂时,选择90%乙醇作为润湿剂制成的软材松散无团块,能全部通过筛网,颗粒成型率为90.01%。
3、药辅比的筛选
以糊精和可溶性淀粉为辅料,以适量的90%或95%乙醇为润湿剂,制作不同药辅比(0.75:1、1:1和1.25:1)软材。过1号筛制粒,60℃干燥1h,整粒。以软材性状、制粒难度和成型率为指标筛选润湿剂的种类。
结果显示,以上各组颗粒的成型率均在90%以上,差异不大。考虑到颗粒的载药量,最终选择糊精或可溶性淀粉与浸膏粉以0.75:1混合进行制粒。
以上对本发明进行了详述。对于本领域技术人员来说,在不脱离本发明的宗旨和范围,以及无需进行不必要的实验情况下,可在等同参数、浓度和条件下,在较宽范围内实施本发明。虽然本发明给出了特殊的实施例,应该理解为,可以对本发明作进一步的改进。总之,按本发明的原理,本申请欲包括任何变更、用途或对本发明的改进,包括脱离了本申请中已公开范围,而用本领域已知的常规技术进行的改变。按附带的权利要求的范围,可以进行一些基本特征的应用。
Claims (5)
1.一种慢痞消颗粒的制备方法,包括如下步骤:
1)将丹参、香橼、太子参、醋延胡索、玉竹、生白术、玫瑰花、乌梅、紫苏梗、白花蛇舌草、砂仁和炙甘草的饮片按比例混合,加水回流进行提取,过滤并收集滤液,得到提取液;
2)对步骤1)所述提取液进行精制以除去杂质,得到精制液;
3)将步骤2)所述精制液浓缩至稠膏,得到浓缩液;
4)将步骤3)所述浓缩液干燥,得到干浸膏;
5)将步骤4)所述干浸膏研磨过筛后与稀释剂混合,加入润湿剂制作软材,将所述软材过筛制粒后干燥、整粒,即得所述慢痞消颗粒;
步骤1)中,各饮片的质量份数如下:丹参10~20份、香橼3~10份、太子参9~30份、醋延胡索3~24份、玉竹6~24份,生白术6~30份、玫瑰花3~18份、乌梅3~12份、紫苏梗5~24份、白花蛇舌草15~60份、砂仁3~6份、炙甘草2~12份;
步骤1)中,所述提取的条件如下:以重量计,第一次加10倍量水提取1~1.5h,第二次在滤渣中加入8倍量水提取1~1.5h,第三次在滤渣中加入8倍量水提取1~1.5h,共提取3次;
步骤2)中,所述精制包括如下步骤:将所述提取液离心,收集上清液;
步骤3)中,60℃测定所述稠膏的密度为1.05g/mL~1.10g/mL;
分三次提取,所述浓缩包括如下步骤:将第一次提取液的精制液浓缩至稠膏,再加入第二次提取液的精制液浓缩至稠膏,再加入第三次提取液的精制液浓缩至稠膏;
步骤4)中,所述干燥为真空干燥;
所述干燥的温度为60~70℃;
步骤5)中,所述干浸膏与所述稀释剂的质量比为(0.75~1.25):1;
所述稀释剂为糊精或可溶性淀粉;
所述润湿剂为质量分数为85%~95%的乙醇的水溶液。
2.根据权利要求1所述的制备方法,其特征在于:步骤2)中,所述离心的转速为2000~5000r/min,时间为15~40min。
3.根据权利要求1-2中任一项所述的制备方法,其特征在于:步骤5)中,所述干浸膏研磨过筛为过4号筛;
所述软材过筛制粒为过1号筛制粒;
所述干燥的温度为60~70℃,时间为30~90min。
4.根据权利要求1-2中任一项所述的制备方法,其特征在于:通过比较柚皮苷、丹酚酸B的转移率和/或比较出膏率优化制备方法;
柚皮苷和丹酚酸B含量的测定采用高效液相色谱法,色谱条件如下:
色谱柱:C18柱,250mm×4.6mm,5μm;
流动相:流动相A为乙酸,流动相B为乙腈,流动相C为水;
洗脱方式:梯度洗脱,洗脱程序如下:0~15min,流动相A的体积分数为3.8%,流动相B的体积分数为15%;15~15.01min,流动相A的体积分数为3.8%,流动相B的体积分数由15%上升至16%;15.01~30min,流动相A的体积分数3.8%,流动相B的体积分数为16%;
流速:1.2mL/min;
柱温:35℃;
检测波长:286nm;
进样量:10μL。
5.权利要求1-4中任一项所述的制备方法制备得到的慢痞消颗粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210581306.5A CN114984159B (zh) | 2022-05-26 | 2022-05-26 | 一种慢痞消颗粒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210581306.5A CN114984159B (zh) | 2022-05-26 | 2022-05-26 | 一种慢痞消颗粒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114984159A CN114984159A (zh) | 2022-09-02 |
CN114984159B true CN114984159B (zh) | 2023-07-21 |
Family
ID=83028675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210581306.5A Active CN114984159B (zh) | 2022-05-26 | 2022-05-26 | 一种慢痞消颗粒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114984159B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925937B (zh) * | 2020-10-27 | 2023-04-25 | 北京中医药大学 | 一种用于阻断慢性胃炎“炎癌转化”的中药组合物 |
-
2022
- 2022-05-26 CN CN202210581306.5A patent/CN114984159B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114984159A (zh) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | A systematic review on botany, processing, application, phytochemistry and pharmacological action of Radix Rehmnniae | |
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN112294869A (zh) | 苓桂术甘汤提取物及其制备方法 | |
WO2019190161A1 (en) | Whole ginseng composition using ginseng roots, leaves and berries and method of preparing the same | |
CN107335029B (zh) | 一种清肠温中颗粒的制备方法 | |
CN1981857A (zh) | 由黄芪、红景天和菝葜制成的药物组合物及其制备方法 | |
CN1977889A (zh) | 一种由黄芪、丹参和苦参素制成的药物组合物及其制备方法 | |
CN114984159B (zh) | 一种慢痞消颗粒及其制备方法 | |
CN103349707B (zh) | 八珍颗粒的制备方法 | |
CN115634275A (zh) | 一种治疗肝癌肝郁脾虚瘀毒证的中药制剂 | |
CN105748652B (zh) | 一种治疗痛风的六月雪胶囊及其制备方法 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN114869923A (zh) | 民族药双参水溶性提取物及其制备方法和应用 | |
CN107095979B (zh) | 一种适用于治疗高血脂症的中药组合物、其制备方法和应用 | |
CN114796417B (zh) | 一种降血糖中药组方及其制备方法 | |
CN117045744B (zh) | 一种补气健脾和/或化痰散结的中药组合物及其制备方法和用途 | |
CN111803576A (zh) | 一种治疗痛风的复方六月雪胶囊 | |
CN118477159B (zh) | 一种用于治疗慢性肝炎的固体制剂及其制备方法 | |
CN108066494A (zh) | 一种夜尿频作用药液及其制备方法 | |
CN111991473B (zh) | 一种益血膏的制备方法 | |
CN112386654B (zh) | 一种中药组合物、提取物及其制备方法与应用 | |
CN106267122A (zh) | 一种栝楼桂枝滴丸及其质量检测方法 | |
CN115501271A (zh) | 一种七清败毒颗粒的制备方法 | |
CN115089642A (zh) | 一种用于治疗2型糖尿病的中药制备方法 | |
CN111686163A (zh) | 一种治疗骨髓增生异常综合症的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |